How much do Sarepta's drugs cost?
Exondys 51 costs around $300,000 per year and Elevidys $3.2 million per dose, making Sarepta's products among the most expensive in medicine — in a disease with a small patient population and, as yet, unconfirmed functional benefit.
Sarepta's products are among the most expensive in medicine. Exondys 51, given by weekly infusion, was priced at around $300,000 a year per patient at launch. Elevidys, the one-time gene therapy, carries a wholesale acquisition cost of $3.2 million. A review in the Annals of Internal Medicine noted that Sarepta's exon-skipping drugs have been controversial partly because of high US prices combined with questionable evidence and delayed confirmatory testing.
Elevidys generated $200.3 million in sales in 2023, its first year. Critics argue that these prices place a heavy burden on Medicaid and private insurers, particularly when benefit has not been confirmed. Sarepta argues its prices reflect the cost of developing therapies for a small, desperately ill population, and the potential lifetime value of slowing a fatal disease. The debate mirrors that over Novartis's Zolgensma.